Restenosis News and Research RSS Feed - Restenosis News and Research

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.
Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University. [More]
Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Four-year results of the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease continue to demonstrate consistent, superior results when compared to bare metal stents (BMS) and percutaneous transluminal angioplasty (PTA) in terms of primary patency, restenosis reduction and revascularization rates. [More]
Tryton Medical received CE Mark for treatment of Left Main Coronary artery disease

Tryton Medical received CE Mark for treatment of Left Main Coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it has received CE Mark for the treatment of Left Main Coronary artery disease. With this approval, Tryton Medical becomes the first company to earn a CE Mark for this indication. [More]
Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

As co-ordinator of the European project ‘ReBioStent’, Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the European Union. [More]
Tryton Medical launches Bifurcation Institute to advance care for bifurcated coronary artery disease

Tryton Medical launches Bifurcation Institute to advance care for bifurcated coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the launch of the Bifurcation Institute. The Bifurcation Institute is a comprehensive education resource established to advance the standard of care for bifurcated coronary artery disease, a common, and often untreated, clinical need. [More]
Auckland physician performs first patient implant of Boston Scientific Innova DES System

Auckland physician performs first patient implant of Boston Scientific Innova DES System

Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed the first patient implant of the Boston Scientific Corporation Innova Drug-Eluting Stent System. [More]
CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium. [More]
New report "Cardiovascular Drug Delivery - Technologies, Markets and Companies"

New report "Cardiovascular Drug Delivery - Technologies, Markets and Companies"

Research and Markets has announced the addition of a new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their offering. [More]
UofL's Diabetes and Obesity Center receives $11.25M COBRE grant from NIH

UofL's Diabetes and Obesity Center receives $11.25M COBRE grant from NIH

​A center created with a five-year National Institutes of Health grant at the University of Louisville in 2008 has won its second five-year grant. [More]
Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). [More]
Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society's highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO's 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta. [More]
New nanoparticle gene delivery method to prevent stenting procedure complications

New nanoparticle gene delivery method to prevent stenting procedure complications

Stent angioplasty saves lives, but there often are side effects and complications related to the procedure, such as arterial restenosis and thrombosis. In the June 2013 issue of The FASEB Journal, however, scientists report that they have discovered a new nanoparticle gene delivery method that may overcome current limitations of gene therapy vectors and prevent complications associated with the stenting procedure. [More]
OrbusNeich introduces COMBO Dual Therapy Stent

OrbusNeich introduces COMBO Dual Therapy Stent

OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents, the current standard of care for the treatment of coronary artery disease. [More]
Drug-eluting stents can keep clogged leg arteries open and prevent leg amputation

Drug-eluting stents can keep clogged leg arteries open and prevent leg amputation

Drug-eluting stents can keep clogged leg arteries open, preventing amputation of the leg, suggests research being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans. [More]
DKCRUSH-III trial results show differences in technically challenging bifurcation lesions

DKCRUSH-III trial results show differences in technically challenging bifurcation lesions

Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Just weeks after the Food and Drug Administration (FDA) approved Cook Medical's Zilver PTX Drug-Eluting Peripheral Stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook's U.S. commercial launch. [More]

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent. [More]
Coronary arteries largely arise from cells of the endocardium

Coronary arteries largely arise from cells of the endocardium

During embryonic development, the all-important coronary arteries arise from cells previously considered incapable of producing them, according to scientists at Albert Einstein College of Medicine of Yeshiva University. [More]
FDA approves Cook's Zilver PTX drug-eluting peripheral stent

FDA approves Cook's Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. [More]
Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD). [More]